Treatment of prostate cancer by hypofractionated radiotherapy

Abstract

Technological advances in radiation therapy delivery have
permitted the use of high dose per fraction radiotherapy for
early stage prostate cancer. Level I evidence supporting
the safety and efficasy of hypofractionated radiotherapy is
evolving. Moderate and extreme hypofractionation regimens
show promising cancer control but long term results of
noninferiority studies of both modalities are required before
use in routine treatment as standard of care.
Keywords: Prostate cancer, Curative radiotherapy,
Moderate and extreme hypo fractionation

Keywords

• Prostate cancer, Curative radiotherapy, Moderate and extreme hypo fractionation

References

1. 1. Dearnaley D, Syndikus I, Sumo G, et al. Conventional versus hypofractionated high dose intensity modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised control trial. Lancet Oncol 2012;13:43-54. doi: 10.1016/S1470- 2045(11)70293-5.
2. 2. Arcangeli G, Saracino B, Gomellini S, et al. A prospective phase III randomised trial of hypofractination versus conventional fractionation in patients with high risk prostate cancer. Int J Radiat Oncol Biol Phys 2008;72:11-18. doi: 10.1016/j.ijrobp.2009.07.1691.
3. 3. Arcangeli G, Strigari L, Gomellini S, et al. Updated results and patterns of failure in a randomized hypofractionation trial for high risk prostate cancer. Int J Radiat Oncol Biol Phys 2012;84:1172-8. doi: 10.1016/j. ijrobp.2012.02.049.
4. 4. Pollack A, Hanlon AL, Horwitz EM, et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys 2006;64:518-26.
5. 5. Pollack A, Walker G, Buyyounouski M, et al. Five year results of a randomized external beam radiotherapy hypofractionation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2011;81(Suppl. 2):S1
6. 6. Kuban D, N.-G. GM, Hamblin L, et al. Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation. Int J Radiat Oncol Biol Phys 2010;78(Suppl. 3):S58-S59.
7. 7. Katz A, Kang J. Stereotactic body radiation therapy for low, intermediate and high risk prostate cancer: disease control and quality of life at 6 years. Int J Radiat Oncol Biol Phys 2013;87:524-5.
8. 8. Loblaw A, Cheung P, D’Alimonte L, et al. Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: toxicity, biochemical, and pathological outcomes. Radiother Oncol 2013;107:153- 8. doi: 10.1016/j.radonc.2013.03.022.

9. 9. Alicikus ZA, Yamada Y, Zhang Z, et al. Ten year outcomes of high dose intensity modulated radiotherapy for localized prostate cancer. Cancer 2011;117:1429- 37. doi: 10.1002/cncr.25467.
10. 10. Chen LN, Suy S, Wang H, et al. Patient reported urinary incontinence following stereotactic body radiation therapy for clinically localized prostate cancer. Radiat Oncol 2014;9:148. doi: 10.1186/1748-717X-9-148.